Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
Study Purpose
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
Eligible Ages | 12 Years - 75 Years |
Gender | All |
Inclusion Criteria:
- - Body weight of ≥ 40 kg at Baseline Visit for participants between ≥ 12 and < 18 years of age.
- - Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years before Baseline Visit and subject meets Hanifin and Rajka criteria.
- - Active moderate to severe AD defined by: - Eczema Area and Severity Index (EASI) score ≥ 16 at the Screening and Baseline Visits; - Validated Investigator's Global Assessment (vIGA) score ≥ 3 at the Screening and Baseline Visits; - ≥ 10% Body surface area (BSA) of AD involvement at the Screening and Baseline Visits; - Baseline weekly average of daily Worst Pruritus NRS ≥ 4.
- - Candidate for systemic therapy or have recently required systemic therapy for AD.
- - Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days before the Baseline Visit.
- - Documented history of inadequate response to topical corticosteroids (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD within 6 months before Baseline Visit.
Exclusion Criteria:
- - Prior exposure to any Janus kinase (JAK) inhibitor.
- - Unable or unwilling to discontinue current atopic dermatitis treatments prior to the study.
- - Requirement of prohibited medications during the study.
- - Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions.
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT03569293 |
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
AbbVie |
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
ABBVIE INC. |
Principal Investigator Affiliation | AbbVie |
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
Overall Status | Active, not recruiting |
Countries | Argentina, Australia, Bosnia and Herzegovina, Bulgaria, Canada, China, Colombia, Croatia, Denmark, Estonia, Finland, France, Germany, Italy, Japan, Malaysia, New Zealand, Puerto Rico, Romania, Russian Federation, Switzerland, Turkey, Ukraine, United Kingdom, United States |
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Atopic Dermatitis |
Study Website: | View Trial Website |
This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, and a 30-day follow-up visit. Participants who meet eligibility criteria in the main study will be randomized in a 1:1:1 ratio to receive a daily oral dose of upadacitinib 30 mg or upadacitinib 15 mg or matching placebo. Upon completion of enrollment of 810 participants in the main study, a supplemental study will continue to enroll adolescents (adolescent sub-study) until a total of 180 adolescent participants are enrolled in the overall study (main study + adolescent sub-study). Randomization for the main study will be stratified by baseline disease severity (validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (United States [US]/Puerto Rico/Canada, Japan, China, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the adolescent sub-study will be stratified by baseline disease severity (moderate [vIGA-AD 3] vs.#46; severe [vIGA-AD 4]) and by geographic region (US/Puerto Rico/Canada and Other). At Week 16 of the main study and the adolescent sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period. In the main study the re-randomization at Week 16 will be stratified by Week 16 50% improvement in Eczema Area and Severity Index [EASI 50] responder [yes/no], geographic region [US/Puerto Rico/Canada, China [Mainland], Japan, and other], and age group [adolescent/adult]. For the adolescent sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other). Participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose. Starting at the Week 4 visit, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary. The Primary Analysis for the main study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the main study and the adolescent sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.
Arms
Placebo Comparator: Placebo / Upadacitinib
Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
Experimental: Upadacitinib 15 mg QD
Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
Experimental: Upadacitinib 30 mg QD
Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
Interventions
Drug: - Placebo for Upadacitinib
Tablets taken orally once a day
Drug: - Upadacitinib
Tablets taken orally once a day
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Alliance Dermatology and MOHs /ID# 200375
Phoenix, Arizona, 85032
Status
Address
Clear Dermatology & Aesthetics Center /ID# 201256
Scottsdale, Arizona, 85255-4134
Status
Address
Bakersfield Derma & Skin Cance /ID# 200433
Bakersfield, California, 93309
Status
Address
First OC Dermatology /ID# 201910
Fountain Valley, California, 92708-3701
Status
Address
California Allergy and Asthma Medical Group /ID# 200727
Los Angeles, California, 90025-7014
Status
Address
Allergy & Asthma Associates of Southern California /ID# 200733
Mission Viejo, California, 92691-6410
Status
Address
Dermatology Clinical Trials /ID# 205876
Newport Beach, California, 92660-7853
Status
Address
UC Davis /ID# 203622
Sacramento, California, 95817
Status
Address
Synergy Dermatology /ID# 200842
San Francisco, California, 94132-1909
Status
Address
San Luis Derm and Laser Clinic /ID# 200372
San Luis Obispo, California, 93405
Status
Address
Stanford University /ID# 200440
Stanford, California, 94305
Status
Address
Care Access Research - Walnut Creek /ID# 200940
Walnut Creek, California, 94598-2488
Status
Address
Dermatology Physicians of Connecticut /ID# 200928
Shelton, Connecticut, 06484-6211
Status
Address
Foxhall Research Center /ID# 213682
Washington, District of Columbia, 20016-4300
Status
Address
Duplicate_George Washington Univ Med /ID# 200364
Washington, District of Columbia, 20037
Status
Address
Clearlyderm Dermatology /ID# 208371
Boca Raton, Florida, 33428
Status
Address
Skin Care Research, LLC /ID# 200811
Boca Raton, Florida, 33486-2269
Status
Address
Olympian Clinical Research /ID# 202914
Clearwater, Florida, 33756
Status
Address
Multi-Speciality Research Associates /ID# 213254
Lake City, Florida, 32055-8835
Status
Address
GSI Clinical Research, LLC /ID# 200849
Margate, Florida, 33063
Status
Address
Florida International Rsrch cr /ID# 218507
Miami, Florida, 33173
Status
Address
Tory P Sullivan, MD PA /ID# 200671
North Miami Beach, Florida, 33162-4708
Status
Address
Leavitt Medical Associates of Florida /ID# 200880
Ormond Beach, Florida, 32174
Status
Address
Precision Clinical Research /ID# 209002
Sunrise, Florida, 33351-7311
Status
Address
Integrated Clinical Research LLC /ID# 200900
West Palm Beach, Florida, 33406-6063
Status
Address
Christie Clinic, LLC /ID# 200427
Champaign, Illinois, 61820
Status
Address
Northwestern University Feinberg School of Medicine /ID# 201644
Chicago, Illinois, 60611-2927
Status
Address
Dawes Fretzin, LLC /ID# 200366
Indianapolis, Indiana, 46256
Status
Address
The South Bend Clinic Center /ID# 200371
South Bend, Indiana, 46617
Status
Address
Clinical Trials Management, LLC - Covington /ID# 212658
Covington, Louisiana, 70433
Status
Address
Clinical Trials Management, LLC - Metairie /ID# 212659
Metairie, Louisiana, 70006-4165
Status
Address
Northeast Dermatology /ID# 201338
Beverly, Massachusetts, 01915
Status
Address
Massachusetts General Hospital /ID# 200474
Boston, Massachusetts, 02114
Status
Address
Integrated Dermatology of Massachusetts, LLC /ID# 209468
Quincy, Massachusetts, 02169
Status
Address
Clin Res Inst of Michigan, LLC /ID# 208019
Chesterfield, Michigan, 48047
Status
Address
Henry Ford Medical Center /ID# 204191
Detroit, Michigan, 48202-3046
Status
Address
Cleaver Dermatology /ID# 202825
Kirksville, Missouri, 63501-5362
Status
Address
Advanced Dermatology of the Midlands /ID# 201689
Omaha, Nebraska, 68144-1105
Status
Address
Clinical Research Consortium /ID# 200734
Las Vegas, Nevada, 89119-5190
Status
Address
AllCutis Research Inc /ID# 200981
Portsmouth, New Hampshire, 03801
Status
Address
Montefiore Medical Center /ID# 200456
Bronx, New York, 10467
Status
Address
Forest Hills Dermatology Group /ID# 209244
Kew Gardens, New York, 11415
Status
Address
Icahn School of Medicine at Mount Sinai /ID# 200370
New York, New York, 10029-6504
Status
Address
J. Schwartz, MD, PLLC /ID# 202121
Troy, New York, 12180-2323
Status
Address
Velocity clinical research /ID# 202653
Cleveland, Ohio, 44122
Status
Address
Lynn Health Science Institute (LHSI) /ID# 212676
Oklahoma City, Oklahoma, 73112
Status
Address
Newton Clinical Research /ID# 204169
Oklahoma City, Oklahoma, 73120-5049
Status
Address
Oregon Medical Res Center PC /ID# 200428
Portland, Oregon, 97223
Status
Address
Oregon Health and Science University /ID# 200992
Portland, Oregon, 97239
Status
Address
Dermdox Dermatology Centers, PC /ID# 213782
Hazleton, Pennsylvania, 18201
Status
Address
Clinical Partners, LLC /ID# 200460
Johnston, Rhode Island, 02919
Status
Address
Coastal Clinical Research Center of the Carolinas /ID# 200402
Charleston, South Carolina, 29414
Status
Address
Arlington Research Center, Inc /ID# 200391
Arlington, Texas, 76011
Status
Address
Orion Clinical Research /ID# 204703
Austin, Texas, 78759-4100
Status
Address
Modern Research Associates, PL /ID# 200705
Dallas, Texas, 75231
Status
Address
Menter Dermatology Res Inst /ID# 200390
Dallas, Texas, 75246
Status
Address
Center for Clinical Studies - Webster TX /ID# 203185
Webster, Texas, 77598
Status
Address
Dermatology Specialists of Spokane /ID# 202068
Spokane, Washington, 99202
International Sites
Status
Address
Framingham Centro Medico /ID# 202688
La Plata, Buenos Aires, 1902
Status
Address
Instituto de Neumonología y Dermatología /ID# 203444
Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, 1425
Status
Address
Psoriahue Med Interdisciplinar /ID# 202451
Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, 1425
Status
Address
Woden Dermatology /ID# 205799
Phillip, Australian Capital Territory, 2606
Status
Address
Holdsworth House Medical Practice /ID# 211236
Darlinghurst, New South Wales, 2010
Status
Address
North Eastern Health Specialists /ID# 205802
Hectorville, South Australia, 5073
Status
Address
Skin Health Institute Inc /ID# 204791
Carlton, Victoria, 3053
Status
Address
Fremantle Dermatology /ID# 205305
Fremantle, Western Australia, 6160
Status
Address
University Clinical Centre of the Republic of Srpska /ID# 202666
Banja Luka, Republika Srpska, 78000
Status
Address
University Clinical Centre of the Republic of Srpska /ID# 202667
Banja Luka, Republika Srpska, 78000
Status
Address
Clinical Center University of Sarajevo /ID# 202668
Sarajevo, , 71000
Status
Address
Clinical Center University of Sarajevo /ID# 202669
Sarajevo, , 71000
Status
Address
UMHAT Alexandrovska EAD /ID# 201519
Sofiya, Sofia, 1431
Status
Address
UMHAT Dr Georgi Stranski EAD /ID# 201521
Pleven, , 5800
Status
Address
UMHAT Professor Stoyan Kirkovich /ID# 201522
Stara Zagora, , 6000
Status
Address
Kirk Barber Research, CA /ID# 200324
Calgary, Alberta, T2G 1B1
Status
Address
Dermatology Research Institute Inc. /ID# 200318
Calgary, Alberta, T2J 7E1
Status
Address
Dr. Chih-ho Hong Medical Inc. /ID# 200311
Surrey, British Columbia, V3R 6A7
Status
Address
Enverus Medical Research /ID# 200307
Surrey, British Columbia, V3V 0C6
Status
Address
Wiseman Dermatology Research /ID# 200323
Winnipeg, Manitoba, R3M 3Z4
Status
Address
Dr. Irina Turchin PC Inc. /ID# 200322
Fredericton, New Brunswick, E3B 1G9
Status
Address
Karma Clinical Trials /ID# 200316
St. John's, Newfoundland and Labrador, A1A 4Y3
Status
Address
Hamilton Health Sciences - McMaster University Medical Centre /ID# 200313
Hamilton, Ontario, L8S 4K1
Status
Address
Dr. Wei Jing Loo Medicine Prof /ID# 206051
London, Ontario, N6H 5L5
Status
Address
Lynderm Research Inc. /ID# 200315
Markham, Ontario, L3P 1X2
Status
Address
Dermatology Ottawa Research Centre /ID# 200319
Ottawa, Ontario, K2C 3N2
Status
Address
K. Papp Clinical Research /ID# 200317
Waterloo, Ontario, N2J 1C4
Status
Address
Dr. David Gratton Dermat Inc. /ID# 200309
Montreal, Quebec, H3H 1V4
Status
Address
Innovaderm Research Inc. /ID# 200320
Montréal, Quebec, H2X 2V1
Status
Address
Dre Angelique Gagne-Henley M.D. inc. /ID# 200326
Saint-Jerome, Quebec, J7Z 7E2
Status
Address
Peking University People's Hospital /ID# 202549
Beijing, Beijing, 100044
Status
Address
Peking University Third Hospital /ID# 202612
Beijing, Beijing, 100191
Status
Address
Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 208597
Guangzhou, Guangdong, 510120
Status
Address
The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 202548
Guangzhou, Guangdong, 510630
Status
Address
The First Hospital of China Medical University /ID# 202615
Shenyang, Liaoning, 110001
Status
Address
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 202554
Shanghai, Shanghai, 200065
Status
Address
The second Affiliated hospital of Zhejiang University school of Medicine /ID# 202608
Hangzhou, Zhejiang, 310009
Status
Address
Beijing Friendship Hospital /ID# 202601
Beijing, , 100032
Status
Address
Huashan Hospital of Fudan University /ID# 205760
Shanghai, , 200040
Status
Address
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 208598
Wuhan, , 420022
Status
Address
Clinisalud del sur /ID# 218100
Medellin, Antioquia, 055422
Status
Address
Fundacion Hospital San Vicente de Paul - Rionegro /ID# 202043
Rionegro, Antioquia, 054040
Status
Address
Ctr Int de Reum del Caribe SAS /ID# 201620
Barranquilla, Atlantico, 80002
Status
Address
Fundacion Centro de Excelencia en Enfermedades Cronicas no Transmisibles - FUNCE /ID# 201905
Monteria, Cordoba, 230002
Status
Address
Klinicki bolnicki centar Zagreb /ID# 201879
Zagreb, Grad Zagreb, 10000
Status
Address
Klinika za dječje bolesti Zagreb /ID# 203151
Zagreb, Grad Zagreb, 10000
Status
Address
Duplicate_Klinicki bolnicki centar Osijek /ID# 201523
Osijek, Osjecko-baranjska Zupanija, 31000
Status
Address
Klinicki bolnicki centar Rijeka /ID# 217423
Rijeka, Primorsko-goranska Zupanija, 51000
Status
Address
Klinicki bolnicki centar Split /ID# 201527
Split, Splitsko-dalmatinska Zupanija, 21000
Status
Address
Bispebjerg and Frederiksberg Hospital /ID# 200979
Copenhagen NV, Hovedstaden, 2400
Status
Address
Herlev and Gentofte Hospital /ID# 200736
Hellerup, Hovedstaden, 2900
Status
Address
Aarhus University Hospital /ID# 200737
Aarhus N, Midtjylland, 8200
Status
Address
North Estonia Medical Centre /ID# 200951
Mustamäe Linnaosa, Harjumaa, 13419
Status
Address
Confido Private Medical Clinic /ID# 200846
Tallinn, Harjumaa, 11313
Status
Address
Tartu University Hospital /ID# 200847
Tartu Linn, Tartumaa, 50406
Status
Address
Mehiläinen Neo /ID# 201116
Turku, Varsinais-Suomi, 20520
Status
Address
Kuopio University Hospital /ID# 202449
Kuopio, , 70210
Status
Address
Terveystalo Tampere /ID# 201117
Tampere, , 33100
Status
Address
HCL - Hôpital Lyon Sud /ID# 201529
Pierre Benite CEDEX, Auvergne-Rhone-Alpes, 69495
Status
Address
CHU de Nantes, Hotel Dieu -HME /ID# 206377
Nantes, Pays-de-la-Loire, 44000
Status
Address
Centre Hospitalier du Mans /ID# 205991
Le Mans CEDEX 9, Sarthe, 72037
Status
Address
Hopital Saint Vincent de Paul /ID# 218253
Lille Cedex, , 59020
Status
Address
Le Bateau BLanc /ID# 206833
Martigues, , 13500
Status
Address
AP-HP - Hopital Necker /ID# 218364
Paris, , 75015
Status
Address
Hôpital Charles-Nicolle /ID# 201525
Rouen, , 76000
Status
Address
CHU Toulouse - Hopital Larrey /ID# 201528
Toulouse, , 31400
Status
Address
Duplicate_Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 202087
Munich, Bayern, 80802
Status
Address
Universitaetsklinikum Frankfurt /ID# 202089
Frankfurt am Main, Hessen, 60590
Status
Address
Universitaetsklinikum Muenster /ID# 202085
Muenster, Nordrhein-Westfalen, 48149
Status
Address
CMS3 Company for Medical Study /ID# 205193
Selters, Rheinland-Pfalz, 56242
Status
Address
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 202255
Kiel, Schleswig-Holstein, 24105
Status
Address
Universitaetsklinikum Bonn /ID# 202086
Bonn, , 53127
Status
Address
TFS Trial Form Support GmbH /ID# 202083
Hamburg, , 20537
Status
Address
Medizinische Hochschule Hannover /ID# 202091
Hannover, , 30625
Status
Address
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 205192
Mainz, , 55131
Status
Address
Fondazione PTV Policlinico Tor Vergata /ID# 201136
Rome, Roma, 00133
Status
Address
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200692
Ancona, , 60126
Status
Address
A.O.U. di Bologna Policlinico S.Orsola-Malpighi /ID# 200746
Bologna, , 40138
Status
Address
A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 200741
Catania, , 95123
Status
Address
Azienda Ospedaliera Universitaria Federico II /ID# 200750
Napoli, , 80131
Status
Address
Azienda Ospedaliero Universitaria Pisana-Stabilimento di Santa Chiara /ID# 200695
Pisa, , 56126
Status
Address
Aichi Medical University Hospital /ID# 202833
Nagakute-shi, Aichi, 480-1195
Status
Address
Fukuoka University Hospital /ID# 201309
Fukuoka-shi, Fukuoka, 814-0180
Status
Address
Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers /ID# 202891
Fukuoka-shi, Fukuoka, 815-8588
Status
Address
Gifu University Hospital /ID# 201760
Gifu-shi, Gifu, 501-1194
Status
Address
Ogaki Municipal Hospital /ID# 203463
Ogaki-shi, Gifu, 503-8502
Status
Address
Takagi Dermatology Clinic /ID# 201238
Obihiro-shi, Hokkaido, 080-0013
Status
Address
Medical Cooperation Kojinkai Sapporo Skin Clinic /ID# 201239
Sapporo-shi, Hokkaido, 060-0063
Status
Address
University Hospital Kyoto Prefectural University of Medicine /ID# 201876
Kyoto-shi, Kyoto, 602-8566
Status
Address
Kume Clinic /ID# 201912
Sakai-shi, Osaka, 5938324
Status
Address
NTT Medical Center Tokyo /ID# 201759
Shinagawa-ku, Tokyo, 141-8625
Status
Address
University of Yamanashi Hospital /ID# 204174
Chuo-shi, Yamanashi, 409-3821
Status
Address
Hospital Raja Permaisuri Bainun /ID# 204375
Ipoh, Perak, 30450
Status
Address
Queen Elizabeth Hospital /ID# 204379
Division Pantai Barat Utara, Sabah, 88200
Status
Address
Hospital Selayang /ID# 204378
Batu Caves, Selangor, 68100
Status
Address
Clinical Trials NZ /ID# 205335
Hamilton, , 3204
Status
Address
Cruz-Santana, Carolina, PR /ID# 201096
Carolina, , 00985
Status
Address
Ponce Medical School Foundation /ID# 201821
Ponce, , 00716-0377
Status
Address
Clinical Research Puerto Rico /ID# 203309
San Juan, , 00909
Status
Address
Spitalul Clinic Colentina /ID# 205860
Bucuresti, , 020121
Status
Address
Cabinet Medical de Dermatovenerologie Dr. Remus Orasan /ID# 205862
Cluj Napoca, , 400105
Status
Address
Chelyabinsk Regional Clinical Dermatovenerologic Dispensary /ID# 201996
Chelyabinsk, Chelyabinskaya Oblast, 454048
Status
Address
Clinical Dermatovenerology Dispensary /ID# 203439
Krasnodar, Krasnodarskiy Kray, 350020
Status
Address
Saratov State Medical University n.a. V.I. Razumovskiy /ID# 201595
Saratov, Saratovskaya Oblast, 410012
Status
Address
Ural Research Institute of dermatovenerology and immunopathology /ID# 201593
Yekaterinburg, Sverdlovskaya Oblast, 620076
Status
Address
National Medical Research Center for Children's Health /ID# 203440
Moscow, , 119296
Status
Address
Universitätsspital Basel /ID# 201599
Basel, Basel-Stadt, 4031
Status
Address
Hôpitaux Universitaires Genève /ID# 201600
Genève, Geneve, 1205
Status
Address
CHUV, Centre hospitalier universitaire vaudois /ID# 200910
Lausanne, Vaud, 1011
Status
Address
CHUV, Centre hospitalier universitaire vaudois /ID# 206505
Lausanne, Vaud, 1011
Status
Address
Inselspital, Universitätsspital Bern /ID# 201598
Bern, , 3010
Status
Address
Erciyes University Medical Fac /ID# 204098
Melikgazi, Kayseri, 38030
Status
Address
Hacettepe University Faculty of Medicine /ID# 204099
Ankara, , 06100
Status
Address
Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 204100
Istanbul, , 34098
Status
Address
Gazi Universitesi Tip Fakultes /ID# 204176
Yenimahalle, , 06560
Status
Address
Military Hospital of Military-Medical Clinical Center of Southern Region /ID# 201962
Zaporizhzhya, Zaporizka Oblast, 69063
Status
Address
ME "Rivne Regional Dermatology and Venereology Dispensary" of RRC /ID# 210504
Rivne, , 33028
Status
Address
West Middlesex University Hospital /ID# 202273
Isleworth, London, City Of, TW7 6AF
Status
Address
Barts Health NHS Trust /ID# 201043
London, London, City Of, E1 2ES
Status
Address
Guy's and St Thomas' NHS Foundation Trust /ID# 201192
London, London, City Of, SE1 9RT
Status
Address
Chelsea and Westminster Hospital NHS Foundation Trust9 /ID# 201971
London, , SW10 9NH
Status
Address
Northern Care Alliance NHS Group /ID# 201194
Salford, , M6 8HD